Nord/LB Reiterates “€58.00” Price Target for Fresenius SE & Co KGaA (FRE)

Nord/LB set a €58.00 ($67.44) price target on Fresenius SE & Co KGaA (FRA:FRE) in a research note published on Wednesday. The firm currently has a buy rating on the stock.

Other research analysts have also recently issued reports about the company. Cfra set a €70.00 ($81.40) target price on Fresenius SE & Co KGaA and gave the stock a buy rating in a research report on Wednesday, October 31st. Commerzbank set a €83.00 ($96.51) target price on Fresenius SE & Co KGaA and gave the stock a buy rating in a research report on Tuesday, October 30th. Warburg Research set a €77.00 ($89.53) target price on Fresenius SE & Co KGaA and gave the stock a buy rating in a research report on Tuesday, October 30th. Barclays set a €80.00 ($93.02) target price on Fresenius SE & Co KGaA and gave the stock a buy rating in a research report on Tuesday, October 30th. Finally, Sanford C. Bernstein set a €83.00 ($96.51) target price on Fresenius SE & Co KGaA and gave the stock a buy rating in a research report on Tuesday, October 30th. Ten investment analysts have rated the stock with a hold rating and ten have given a buy rating to the company. The company has an average rating of Buy and a consensus target price of €60.18 ($69.98).

FRA FRE opened at €48.74 ($56.67) on Wednesday. Fresenius SE & Co KGaA has a one year low of €60.16 ($69.95) and a one year high of €80.00 ($93.02).

Fresenius SE & Co KGaA Company Profile

Fresenius SE & Co KGaA, a health care group, provides products and services for dialysis, hospitals, and outpatient medical care worldwide. The company operates through Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed segments. The Fresenius Medical Care segment offers products for patients with chronic kidney failure.

Featured Story: Dollar Cost Averaging

Analyst Recommendations for Fresenius SE & Co KGaA (FRA:FRE)

Receive News & Ratings for Fresenius SE & Co KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius SE & Co KGaA and related companies with MarketBeat.com's FREE daily email newsletter.